

Corporate Seminar

🇯 Japanese Session / 🇬 English Session

13-Oct (Fri) 12:25–13:10

🇬LS1-1 Past Present and Future of Lymphoma Staging and Response Assessment

【No. 1 Tokyo International Forum 4F Hall C】

Chair Takanori Teshima (Department of Hematology, Hokkaido University)
Speaker Bruce David Cheson (Lymphoma Research Foundation and Center for Cancer and Blood Disorders)
Sponsor SymBio Pharmaceuticals Limited

🇯LS1-2 Up to Date on CML Treatment ~ATP-competitive TKI and STAMP Inhibitor~

【No. 2 Tokyo International Forum 7F Hall B7 ①】

Chair Itaru Matsumura (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan)
Speaker Tomoiku Takaku (Division of Hematology, Juntendo University School of Medicine, Tokyo, Japan)
Sponsor Novartis Pharma K.K.

🇬LS1-3 Optimal role of CAR T-cells in Diffuse Large B-cell Lymphoma

【No. 3 Tokyo International Forum 7F Hall B7 ②】

Chair Naoki Hosen (Immunology Frontier Research Center, Osaka University)
Speaker Jeremy S. Abramson (Massachusetts General Hospital, Jon and Jo Ann Hagler Center for Lymphoma, Harvard Medical School)
Sponsor Bristol Myers Squibb

🇯LS1-4 Follicular Lymphoma and Epigenetics: Basic Knowledge for Clinical Approaches

【No. 4 Tokyo International Forum 5F Hall B5 ①】

Chair Kazuyuki Shimada (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
Speaker Daisuke Ennishi (Center for Genomic Medicine Promotion, Okayama University Hospital)
Sponsor Eisai Co., Ltd.

LS1-5 Management of AL amyloidosis patients in Kumamoto University Hospital Amyloidosis Center

[No. 5 Tokyo International Forum 5F Hall B5 ②]

- Chair** Ichiro Hanamura (Division of Hematology, Department of Internal Medicine, Aichi Medical University, Japan)
- Speaker** Yawara Kawano (Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan)
- Sponsor** Janssen Pharmaceutical K.K.

LS1-6 Positioning of the 4 Sarclisa®-based regimens considered from basic and clinical perspectives.

[No. 6 Tokyo International Forum 7F Hall D7]

- Chair** Chihiro Shimazaki (JCHO Kyoto Kuramaguchi Medical Center)
- Speaker** Hideto Tamura (Division of Diabetes, Endocrinology and Hematology, Dokkyo Medical University Saitama Medical Center)
- Speaker** Shigeki Ito (Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine)
- Sponsor** Sanofi K.K.

LS1-7 Deciphering the mechanisms of high sensitivity of CD4-positive lymphoid malignancies to HDAC inhibitors

[No. 7 Tokyo International Forum 5F Hall D5]

- Chair** Kenji Ishitsuka (Department of Hematology and Rheumatology, Kagoshima University)
- Speaker** Yusuke Furukawa (Center for Medical Education, Teikyo University of Science/Center for Molecular Medicine, Jichi Medical University)
- Sponsor** Meiji Seika Pharma Co., Ltd.

**LS1-8 Hemophilia care in pediatrics
~How to make the transition to adult care and support as smooth as possible**

[No. 8 Tokyo International Forum 1F Hall D1]

- Chair** Makoto Kaneda (Sapporo Tokushukai Hospital Pediatrics, Hemophilia treatment center)
- Speaker** Fuminori Iwasaki (Division of Hematology / Oncology, Kanagawa Children's Medical Center)
- Sponsor** CSL Behring K.K.

**LS1-9 Potential of single agents for PTCL
~Our experience of Pralatrexate treatment~**

[No. 9 Tokyo International Forum 4F G402]

- Chair** Shigeru Kusumoto (Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital)
- Speaker** Tomonori Nakazato (Department of Hematology, Yokohama Municipal Citizen's Hospital)
- Sponsor** Mundipharma K.K.

LS1-10 Redefining treatment goals in PNH

[No. 10 Tokyo International Forum 4F G409]

- Chair** Yuzuru Kanakura (Sumitomo Hospital)
Speaker Jeffery Szer (Department of Clinical Haematology, Peter MacCallum Cancer Centre & The Royal Melbourne Hospital and Department of Medicine, University of Melbourne)
Sponsor Swedish Orphan Biovitrum Japan Co., Ltd. / Asahi Kasei Pharma Corporation

LS1-11 Aplastic Anemia Up to Date

[No. 11 Tokyo International Forum 5F G502]

- Chair** Shigeru Chiba (Department of Hematology, Institute of Medicine, University of Tsukuba)
Speaker Yasuyoshi Morita (Department of Hematology and Rheumatology, Kindai University Faculty of Medicine)
Sponsor Kyowa Kirin Co.,Ltd.

LS1-12 SDGs from the Perspective of Multiple Myeloma

[No. 12 Tokyo International Forum 5F G510]

- Chair** Yousuke Minami (National Cancer Center Hospital East)
Speaker Toru Kiguchi (Dokkyo Medical University Mdeical Center)
Sponsor Fuji Pharma

LS1-13 Companion diagnostics (CDx) for AML, when and to whom best used.

[No. 13 Tokyo International Forum 6F G602]

- Chair** Yuichi Ishikawa (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
Speaker Naoko Hosono (University of Fukui Hospital, Department of Blood Transfusion)
Sponsor Invivoscribe / LabPMM

LS1-14 Diagnosis and treatment for myeloid/lymphoid neoplasms with various conditions

[No. 14 Tokyo International Forum 6F G610]

- Chair** Masafumi Ito (Department of Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital)
Points of revision in the WHO classification 5th edition and the importance of differential diagnosis
Speaker Masafumi Ito (Department of Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital)
The latest treatment strategy for FGFR1 positive Myeloid/Lymphoid Neoplasms
Speaker Noriaki Kawano (Department of Hematology, Miyazaki Prefectural Miyazaki Hospital)
Sponsor Incyte Japan G.K.

■LS1-15 ECP Treatment for Second Line cGvHD

【No. 15 Tokyo International Forum 7F G701】

- Chair** Yasuyuki Arai (Center for Research and Application of Cellular Therapy (C-RACT) Kyoto University Hospital, Kyoto, JAPAN)
- Speaker** Robert Zeiser (Tumor Immunology and Immune Modulation, Medical Center of the University of Freiburg, Germany)
- Sponsor** Mallinckrodt Pharmaceuticals

14-Oct (Sat) 12:00–12:45

■LS2-1 Multiple myeloma and anti-CD38 monoclonal antibody –rationale, evidence and reality–

【No. 1 Tokyo International Forum 4F Hall C】

- Chair** Shuji Ozaki (Tokushima Prefectural Central Hospital Department of Hematology)
- Speaker** Junya Kuroda (Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Japan)
- Sponsor** Janssen Pharmaceutical K.K.

■LS2-2 Multiple myeloma treatment strategy in consideration of the patient's well-being

【No. 2 Tokyo International Forum 7F Hall B7 ①】

- Chairs** Makoto Sasaki (Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan)
Masahiro Abe (Professor Emeritus, Tokushima University Department of Hematology, Kawashima Hospital)
- Progress in myeloma treatment: a patients' perspective**
- Speaker** Masahiro Abe (Professor Emeritus, Tokushima University Department of Hematology, Kawashima Hospital)
- MM treatment strategies based on the patient issue**
– Significance of Ixazomib maintenance therapy regarding to the latest guideline –
- Speaker** Makoto Sasaki (Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan)
- Sponsor** Takeda Pharmaceutical Company Limited

■LS2-3 Treatment Strategies for Refractory Myeloma in the CAR-T Era: Current Status and Future Perspectives

【No. 3 Tokyo International Forum 7F Hall B7 ②】

- Chair** Yoichi Imai (Department of Hematology and Oncology, Dokkyo Medical University)
- Speaker** Satoshi Yoshihara (Department of Respiratory Medicine and Hematology, Hyogo Medical University)
- Sponsor** Bristol Myers Squibb

■LS2-4 Recent advances in the treatment strategies of MPN

【No. 4 Tokyo International Forum 5F Hall B5 ①】

Chair Kazuya Shimoda (Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan)

Light up the new world of PV treatment

Speaker Tomoki Ito (KANSAI MEDICAL UNIVERSITY, First Department of Internal Medicine, Osaka, Japan)

Update on Myelofibrosis Management

Speaker Katsuto Takenaka (Department of Hematology, Clinical Immunology and Infectious Diseases Ehime University Graduate School of Medicine, Ehime, Japan)

Sponsor Novartis Pharma K.K.

■LS2-5 Current SoC in DLBCL treatment – CAR T vs Chemo/ASCT –

【No. 5 Tokyo International Forum 5F Hall B5 ②】

Chair Koji Izutsu (Department of Hematology, National Cancer Center Hospital)

Speaker Frederick Locke (Moffitt Cancer Center, Tampa, FL, USA)

Sponsor Gilead Sciences K.K.

■LS2-6 Considering the Clinical Question of DLBCL

【No. 6 Tokyo International Forum 7F Hall D7】

Chair Kenichi Ishizawa (Tohoku Fukushi University Faculty of Health Science)

Speaker Hiroyuki Takahashi (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)

Speaker Nobuhiko Yamauchi (Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)

Sponsor Chugai Pharmaceutical Co., Ltd.

■LS2-7 Hematologist's Approach for Differential Diagnosis –Inherited Metabolic Diseases with Splenomegaly

【No. 7 Tokyo International Forum 5F Hall D5】

Chair Kazuhiko Yamamoto (Department of Hematology, Okayama City Hospital)

Speaker Makoto Yoshimitsu (Kagoshima University, Graduate School of Medical and Dental Sciences, Department of Hematology and Rheumatology)

Sponsor Sanofi K.K.

**LS2-8 Diagnosis and Treatment of Paroxysmal Nocturnal Hemoglobinuria
~Based on the Guide for Paroxysmal Nocturnal Hemoglobinuria,
2022~**

[No. 8 Tokyo International Forum 1F Hall D1]

- Chair** Junichi Nishimura (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
Speaker Shikiko Ueno (Department of Blood Transfusion and Cell Therapy, Kumamoto University Hospital)
Sponsor Alexion Pharma GK

LS2-9 The Frontiers of Aplastic Anemia Treatment

[No. 9 Tokyo International Forum 4F G402]

- Chair** Shinji Nakao (Japanese Red Cross Ishikawa Blood Center)
Positioning of the novel therapeutic drug “horse ATG”
Speaker Yoshinobu Kanda (Division of Hematology, Jichi Medical University)
Key Points for Revision of the Reference Guide for Aplastic Anemia
Speaker Hirohito Yamazaki (Division of Transfusion Medicine, Kanazawa University Hospital)
Sponsor Pfizer Japan Inc.

LS2-10 Positioning of Venetoclax+Azacitidine in AML treatment

[No. 10 Tokyo International Forum 4F G409]

- Chair** Koichi Akashi (Department of Medicine and Biosystemic Science, Faculty of Medicine, Kyushu University)
Speaker Goichi Yoshimoto (Department of Hematology, Saga-ken Medical Center Koseikan)
Sponsor AbbVie GK

**LS2-11 Treatment Modalities for Relapsed/Refractory Malignant Lymphoma
: Focusing on B-cell lymphoma and consolidation therapy**

[No. 11 Tokyo International Forum 5F G502]

- Chair** Takashi Ikeda (Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center)
Speaker Kentaro Fukushima (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
Sponsor Sumitomo Pharma Co.,Ltd.

LS2-12 The pathogenesis and treatment strategies for DIC developed in association with APL

[No. 12 Tokyo International Forum 5F G510]

- Chair** Hiroyuki Fujita (Hematology Department, Saiseikai Yokohama Nanbu Hospital)
Speaker Takayuki Ikezoe (Department of Hematology, Fukushima Medical University)
Sponsor Asahi Kasei Pharma Corporation

■LS2-13 Management of primary CNS lymphoma—current status and future directions

【No. 13 Tokyo International Forum 6F G602】

- Chair** Eisei Kondo (Department of Hematology, Kawasaki medical school)
Speaker Lakshmi Nayak (The Center for CNS Lymphoma within the Center for Neuro-Oncology, Dana-Farber Cancer Institute, Neurology at Harvard Medical School)
Sponsor ONO PHARMACEUTICAL CO., LTD.

■LS2-14 Treatment strategy for transplant-ineligible patients with relapsed or refractory ALL

【No. 14 Tokyo International Forum 6F G610】

- Chair** Yasushi Miyazaki (Atomic Bomb Disease Institute, Nagasaki University)
Speaker Shuichi Ota (Sapporo Hokuyu Hospital)
Sponsor Amgen K.K. / Astellas Pharma Inc.

■LS2-15 Fungal infection management on hematopoietic cancer treatment

【No. 15 Tokyo International Forum 7F G701】

- Chair** Noriko Doki (Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital)
Speaker Tadakazu Kondou (Hematology Department, Kobe City Medical Center General Hospital)
Sponsor MSD K.K.

15-Oct (Sun) 12 : 05—12 : 50

■LS3-1 Bispecific Antibodies for Relapsed / Refractory DLBCL

【No. 1 Tokyo International Forum 4F Hall C】

- Chair** Hirokazu Nagai (NHO Nagoya Medical Center)
Speaker Shinichi Makita (National Cancer Center Hospital)
Sponsor Genmab K.K. / AbbVie G.K.

■LS3-2 How to use the Sarclisa®-based regimen in the 2nd line therapy.

【No. 2 Tokyo International Forum 7F Hall B7 ①】

- Chair** Kenshi Suzuki (Department of Myeloma-Amyloidosis center, Japanese Red Cross Medical Center)
Speaker Keichiro Mihara (Department of Cellular Immunotherapies for Cancer, International Center for Cell and Gene Therapy, Fujita Health University)
Speaker Kazuhito Suzuki (The Jikei University School of Medicine)
Sponsor Sanofi K.K.

LS3-3 Cutting edge treatment strategy for PV

Live Recording On-demand

[No. 3 Tokyo International Forum 7F Hall B7 ②]

- Chair** Keita Kirito (Department of Hematology/Oncology, University of Yamanashi, Japan)
- Speaker** Jean-Jacques Kiladjian (Clinical Pharmacology, Paris Cité University Clinical Investigation Centre, Saint Louis Hospital, Paris, France.)
- Sponsor** PharmaEssentia Japan KK

LS3-4 Role of quizartinib in first-line treatment for FLT3-ITD mutated AML

[No. 4 Tokyo International Forum 5F Hall B5 ①]

- Chair** Takahiro Yamauchi (Department of Hematology and Oncology, University of Fukui)
- Speaker** Pau MONTESINOS FERNÁNDEZ (Hospital Universitari i Politècnic La Fe, Valencia, Spain)
- Sponsor** Daiichi Sankyo Co., Ltd.

LS3-5 Treatment strategies for FLT3 gene mutation-positive AML based on progress in AML drugs

[No. 5 Tokyo International Forum 5F Hall B5 ②]

- Chair** Satoru Takada (Department of Hematology, Saiseikai Maebashi Hospital, Gunma Prefecture)
- Speaker** Hitoshi Kiyoi (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)
- Sponsor** Astellas Pharma Inc.

LS3-6 Strategies for the Management of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome with HokUS

[No. 6 Tokyo International Forum 7F Hall D7]

- Chair** Ken-ichi Matsuoka (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine)
- Speaker** Junichi Sugita (Department of Hematology, Sapporo Hokuyu Hospital)
- Sponsor** Nippon Shinyaku Co., Ltd.

LS3-7 Ph+ Leukemia: The Landscape of Diagnosis and Treatment

[No. 7 Tokyo International Forum 5F Hall D5]

- Chair** Chikashi Yoshida (Department of Hematology, National Hospital Organization Mito Medical Center)
- Speaker** Koji Sasaki (Department of Leukemia The University of Texas MD Anderson Cancer Center, Houston TX, U.S.A.)
- Sponsor** Otsuka Pharmaceutical Co., Ltd.

■LS3-8 Treatment strategy and MoA for CLL

[No. 8 Tokyo International Forum 1F Hall D1]

- Chair** Junji Suzumiya (Department of Hematology, Koga Community Hospital)
- Speaker** Dai Maruyama (Cancer Institute Hospital, Japanese Foundation for Cancer Research)
- Sponsor** Eli Lilly Japan K.K.

■LS3-9 Novel target of primary immune thrombocytopenia ~Unraveling neonatal Fc receptor (FcRn)~

[No. 9 Tokyo International Forum 4F G402]

- Chair** Mitsuru Murata (Clinical Medicine Research Center, International University of Health and Welfare)
- Speaker** Yoshitaka Miyakawa (Department of Hematology, Saitama Medical University)
- Sponsor** argenx Japan K.K. Medical Affairs

■LS3-10 Treatment strategies for PTCL – including new drug treatments –

[No. 10 Tokyo International Forum 4F G409]

- Chair** Kunihiro Tsukasaki (Department of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan.)
- Speaker** Go Yamamoto (Department of Hematology, Toranomon Hospital, Japan.)
- Sponsor** Nippon Kayaku Co.,Ltd.

■LS3-11 Acquired Hemophilia A A Comprehensive Guide from Diagnosis to Treatment

[No. 11 Tokyo International Forum 5F G502]

- Chair** Takashi Sonoki (Department of Hematology/Oncology, Wakayama Medical University)
- Speaker** Masato Bingo (Department of Laboratory medicine, Tokyo Medical University)
- Sponsor** Takeda Pharmaceutical Company Limited

■LS3-12 Facts and Challenges in Treatment of Iron Deficiency Anemia ~The New Normal in Oral Iron Preparations~

[No. 12 Tokyo International Forum 5F G510]

- Chair** Norio Komatsu (Department of Hematology, Juntendo University School of Medicine)
- Speaker** Tohru Fujiwara (Department of Laboratory Medicine, Iwate Medical University School of Medicine)
- Sponsor** Medical Affairs Department, Torii Pharmaceutical Co., Ltd.

LS3-13 Mechanism of action and characteristics of a novel ITP treatment; syk inhibitor, fostamatinib

[No. 13 Tokyo International Forum 6F G602]

- Chair** Yoshiaki Tomiyama (Uegahara Hospital)
Speaker Masataka Kuwana (Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine)
Sponsor KISSEI PHARMACEUTICAL CO., LTD.

LS3-14 Latest updates in treatment of CLL

[No. 14 Tokyo International Forum 6F G610]

- Chair** Masashi Sawa (Department of Hematology and Oncology, Anjo Kosei Hospital)
Speaker Paolo Ghia (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy)
Sponsor AstraZeneca K.K.

LS3-15 Current topics on antimicrobial resistant Gram-negative infections in patients with hematological malignancies

[No. 15 Tokyo International Forum 7F G701]

- Chair** Hiromichi Iwasaki (Department of Infection Control and Prevention Faculty of Medical Sciences University of Fukui)
Speaker Hideki Araoka (Department of Infectious Diseases, Toranomon Hospital)
Sponsor Shionogi & Co., Ltd.

13-Oct (Fri) 17:00–17:45

ES1-3 Challenges in cord blood transplantation, - including fungal infection management -

[No. 3 Tokyo International Forum 7F Hall B7 ②]

- Chair** Takehiko Mori (Department of Hematology, Tokyo Medical and Dental University)
Speaker Satoshi Takahashi (Division of Clinical Precision Research Platform, Department of Hematology / Oncology, The Institute of Medical Science, The University of Tokyo)
Sponsor Asahi Kasei Pharma Corporation

ES1-4 Chronic Myeloid Leukemia: comorbidities and treatment choice

[No. 4 Tokyo International Forum 5F Hall B5 ①]

- Chair** Naoto Takahashi (Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan)
Speaker Takeshi Kondo (Department of Hematology, Aiiiku Hospital, Sapporo, Japan)
Sponsor Pfizer Japan Inc.

ES1-5 Immunotherapy and immune microenvironment in Multiple Myeloma

[No. 5 Tokyo International Forum 5F Hall B5 ②]

- Chair** Hideo Harigae (Hematology, Tohoku University Graduate School of Medicine)
Speaker Kyohei Nakamura (QIMR Berghofer Medical Research Institute)
Sponsor Janssen Pharmaceutical K.K.

ES1-6 Which allo-immune response is most effective against leukemia?

[No. 6 Tokyo International Forum 7F Hall D7]

- Chair** Shuichi Taniguchi (Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan)
Speaker Yoshinobu Maeda (Department of Hematology, Oncology and Respiratory Medicine, Okayama University Academic Field of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan)
Sponsor Novartis Pharma K.K.

ES1-7 Myelofibrosis – Emerging Treatment and Biological Concepts

[No. 7 Tokyo International Forum 5F Hall D5]

- Chair** Michiko Ichii (Department of Hematology and Oncology, Osaka University Hospital)
Speaker Raajit K. Rampal (Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, USA)
Sponsor Sumitomo Pharma Co.,Ltd.

ES1-8 Brand-new treatment strategy for peripheral T-cell lymphoma (PTCL)

[No. 8 Tokyo International Forum 1F Hall D1]

- Chair** Kazuhito Yamamoto (Aichi Cancer Center)
Speaker Ritsuro Suzuki (Department of Hematology and Oncology, Faculty of Medicine, Shimane University)
Sponsor Takeda Pharmaceutical Company Limited

ES1-9 Significance of Obinutuzumab treatment for untreated follicular lymphoma

~Based on the final results from the GALLIUM study~

[No. 9 Tokyo International Forum 4F G402]

- Chair** Yasuhito Terui (Department of Hematology, Saitama Medical University Hospital)
Speaker Hirohiko Shibayama (Department of Hematology, National Hospital Organization Osaka National Hospital)
Sponsor Chugai Pharmaceutical Co., Ltd. / Nippon Shinyaku Co., Ltd.

ES1-10 What we learned from the COVID-19 pandemic and how to prepare for what comes next – including how to use effective therapeutics.

[No. 10 Tokyo International Forum 4F G409]

- Chair** Akihumi Takaori (Department of Hematology / Oncology, Graduate School of Medicine, Kyoto University)
- Speaker** Kazuhiro Tateda (Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Japan)
- Sponsor** AstraZeneca K.K.

ES1-11 Management of CLL in the era of targeted therapies

[No. 11 Tokyo International Forum 5F G502]

- Chair** Mineo Kurokawa (Department of Hematology and Oncology, Department of Cell Therapy and Transplantation Medicine, The University of Tokyo)
- Speaker** Tomohiko Kamimura (Department of Hematology, Harasanshin Hospital)
- Sponsor** abbvie GK

ES1-12 CMV infection in allo HSCT, where are we going?

[No. 12 Tokyo International Forum 5F G510]

- Chair** Keisuke Kataoka (Division of Hematology, Keio University School of Medicine / Division of Molecular Oncology, National Cancer Center Research Institute)
- Speaker** Yuta Katayama (Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan)
- Sponsor** MSD K.K.

ES1-13 Practical Insights and Considerations for the Anti-complement Drug in Treating Cold Agglutinin Disease

[No. 13 Tokyo International Forum 6F G602]

- Chair** Hideho Wada (Department of Hematology, Kawasaki Medical School)
- Speaker** Yasutaka Ueda (Department of Hematology & Oncology, Osaka University Graduate School of Medicine)
- Sponsor** Sanofi K.K.

ES1-14 Evolution of Hematologic Oncology Treatment and Control of Infection Associated with Hypogammaglobulinemia

Live Recording On-demand

[No. 14 Tokyo International Forum 6F G610]

- Chair** Ken Ohmachi (Tokai University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology)
- Speaker** Hitoshi Hanamoto (Department of Hematology, Kindai University Nara Hospital)
- Sponsor** CSL Behring K.K.

ES1-15

【No. 15 Tokyo International Forum 7F G701】

Chair Naohiro Sekiguchi (Department of Hematology, National Hospital Organization Disaster Medical Center)

Genetic abnormalities and therapeutic strategies in WM/LPL

Speaker Steven P Treon (Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School)

The importance of shared decision making (SDM) and the role and practice of SDM in the treatment of WM/LPL

Speaker Christopher J Patterson (Bing Center for Waldenström's Macroglobulinemia, Harvard Medical School)

Sponsor ONO PHARMACEUTICAL CO., LTD.

14-Oct (Sat) 17:00–17:45

ES2-3 Expert Guidance on Therapeutic Strategies for Relapsed/Refractory Myeloma

【No. 3 Tokyo International Forum 7F Hall B7 ②】

Chair Shinsuke Iida (Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences)

How I Treat Lenalidomide-exposed RRMM and Triple-class exposed RRMM

Speaker Larry D. Anderson (UT Southwestern Medical Center)

Sponsor Bristol Myers Squibb

ES2-4 New Treatment Options for Iron Deficiency Anemia ~Ferric Derisomaltose, a high-dose intravenous iron preparation~

【No. 4 Tokyo International Forum 5F Hall B5 ①】

Chair Takahiro Suzuki (Department of Hematology, Kitasato University School of Medicine, Kanagawa, Japan)

Speaker Hiroshi Kawabata (Department of Hematology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan)

Sponsor Nippon Shinyaku Co., Ltd.

ES2-5 The Role of Ibrutinib in steroid-resistant/dependent chronic GVHD

【No. 5 Tokyo International Forum 5F Hall B5 ②】

Chair Koji Kato (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)

Pathophysiology and Treatment of Chronic Graft-versus-Host Disease

Speaker Yoshihiro Inamoto (Department of BMT and Cellular Therapy, Fujita Health University)

How I use Ibrutinib for cGVHD & Practice sharing

Speaker Masako Toyosaki (Department of Hematology and Oncology, Tokai University School of Medicine)

Sponsor Janssen Pharmaceutical K.K.

ES2-6 Lessons learned from CD19 CAR therapy

[No. 6 Tokyo International Forum 7F Hall D7]

- Chair** Koji Tamada (Yamaguchi University Graduate School of Medicine, Department of Immunology)
Speaker Michel Sadelain (Memorial Sloan Kettering Cancer Center)
Sponsor Gilead Sciences K.K.

ES2-7 Thrombotic Thrombocytopenic Purpura

[No. 7 Tokyo International Forum 5F Hall D5]

- Chair** Masanori Matsumoto (Departments of Hematology and Blood Transfusion Medicine, Nara Medical University)

Revisions of diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2023

- Speaker** Masanori Matsumoto (Departments of Hematology and Blood Transfusion Medicine, Nara Medical University)

Treatment experiences for immune-mediated thrombotic thrombocytopenic purpura (iTTP) and Case studies of Caplacizumab at Wakayama Medical University Hospital

- Speaker** Toshiki Mushino (Department of Hematology, Wakayama Medical University Hospital)
Sponsor Sanofi K.K.

ES2-8 How to manage secondary immunodeficiency in patients with hematological malignancies.

[No. 8 Tokyo International Forum 1F Hall D1]

- Chair** Hirohisa Nakamae (Department of Hematology, Osaka Metropolitan University Graduate School of Medicine)
Speaker Tomomi Tobai (Department of Hematology, Yamagata University hospital)
Sponsor Takeda Pharmaceutical Company Limited

ES2-9 New developments in the treatment of acquired haemophilia A.

[No. 9 Tokyo International Forum 4F G402]

- Chair** Jun Yamanouchi (Division of Blood Transfusion and Cell Therapy, Ehime University Hospital)
Speaker Satoshi Higasa (Department of Respiratory Medicine and Hematology, Hyogo Medical University)
Sponsor Chugai Pharmaceutical Co., Ltd.

**ES2-10 The Importance of Biomarker-Guided Therapy in CLL
-Latest updates and insights from ERIC led initiatives-**

[No. 10 Tokyo International Forum 4F G409]

- Chair** Yoshikane Kikushige (Center for Cellular and Molecular Medicine, Kyushu University Hospital)
- Speaker** Paolo Ghia (Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy)
- Sponsor** AstraZeneca K.K.

**ES2-11 Current status and future perspectives of diffuse large B-cell lymphoma.
~ Expectations for FN management in the use of G-LASTA Subcutaneous Injection 3.6mg BodyPod.~**

[No. 11 Tokyo International Forum 5F G502]

- Chair** Chiaki Nakaseko (Department of Hematology, International University of Health and Welfare School of Medicine)
- Speaker** Junichiro Yuda (National Cancer Center Hospital East Department of Hematology and Experimental Therapeutics / Hematological Treatment Development Promotion Office, Department for the Promotion of Drug and Diagnostic Development)
- Sponsor** Kyowa Kirin Co., Ltd.

ES2-12

Live Recording On-demand

[No. 12 Tokyo International Forum 5F G510]

- Chair** Akihiko Goto (Department of Hematology, Tokyo Medical University, Tokyo, Japan)
- Recent strategy of ITP treatment and thrombopoietin receptor agonists**
- Speaker** Hirokazu Kashiwagi (Department of Blood Transfusion, Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan)
- Aplastic Anemia: Current Therapeutic Strategy and Positioning of Eltrombopag**
- Speaker** Naoshi Obara (University of Tsukuba, Ibaraki, Japan)
- Sponsor** Novartis Pharma K.K.

ES2-13 Current status and challenges in the treatment for mold infections

[No. 13 Tokyo International Forum 6F G602]

- Chair** Toshihiro Miyamoto (Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University)
- Speaker** Shinsuke Takagi (Department of Hematology, Toranomon Hospital)
- Sponsor** Sumitomo Pharma Co., Ltd.

ES2-14 The Emerging role of Immune Checkpoint Inhibitors in the treatment of malignant lymphoma

[No. 14 Tokyo International Forum 6F G610]

- Chair** Motoko Yamaguchi (Department of Hematological Malignancies, Mie University Graduate School of Medicine)
Speaker Wataru Munakata (Department of Hematology, National Cancer Center Hospital)
Sponsor MSD K.K.

ES2-15 Cutting-edge treatment approach for lenalidomide refractory myeloma patients

[No. 15 Tokyo International Forum 7F G701]

- Chair** Tadao Ishida (Japanese Red Cross Medical Center Department of Hematology / Myeloma-Amyloidosis Center)
Speaker Hang Quach (Clinical Haematology Service / Clinical Haematology Research, St Vincent's Hospital Melbourne, University of Melbourne)
Sponsor ONO PHARMACEUTICAL CO., LTD.

14-Oct (Sat) 8 : 00 – 8 : 45

MS2-3 The Role of Daratumumab in Transplant-ineligible Multiple Myeloma –From Clinical Practice and Evidence Perspective–

[No. 3 Tokyo International Forum 7F Hall B7 ②]

- Chair** Yasushi Takamatsu (Division of Medical Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University)

A clinical perspective on the treatment of multiple myeloma from initial therapy to relapsed and refractory disease ~ towards optimizing outcome and translating current advances to real world practice.

- Speaker** Paul Richardson (Dana Farber Cancer Institute/Harvard Medical School)

The promising potential hidden in Daratumumab for elderly myeloma patients with diverse backgrounds

- Speaker** Yuichi Horigome (Department of Hematology, Kitasato University Graduate School of Medicine Sciences)
Sponsor Janssen Pharmaceutical K.K.

MS2-4 CAR-T cell therapy in relapsed/refractory DLBCL and relapsed/refractory FL

Live Recording On-demand

[No. 4 Tokyo International Forum 5F Hall B5 ①]

- Chair** Hideki Goto (Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Hokkaido, Japan)
Speaker Noriko Fukuhara (Department of Hematology, Tohoku University Hospital, Miyagi, Japan)
Sponsor Novartis Pharma K.K.

MS2-5 Precision medicine in myeloma – a new frontier

[No. 5 Tokyo International Forum 5F Hall B5 ②]

- Chair** Hiroshi Handa (Department of Hematology, Gunma University Hospital)
- Speaker** Shaji Kumar (Division of Hematology, Department of Internal Medicine, Mayo Clinic)
- Sponsor** AbbVie GK

MS2-6 Clinical practice of genetic panel tests for hematological malignancies

[No. 6 Tokyo International Forum 7F Hall D7]

- Chair** Takahiro Maeda (Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences)
- Speaker** Yasuhito Nannya (Department of Hematology and Oncology, Institute of Medical Science Research Hospital, the University of Tokyo)
- Sponsor** Astellas Pharma Inc. Medical Affairs

MS2-7 Successful interprofessional work (IPW) in autologous stem-cell collection and transplantation

[No. 7 Tokyo International Forum 5F Hall D5]

- Chair** Kazutaka Sunami (Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan)
- Speaker** Nobuhiro Tsukada (Department of Hematology, Japanese Red Cross Medical Center, Japan)
- Sponsor** Sanofi K.K.

MS2-8

[No. 8 Tokyo International Forum 1F Hall D1]

- Chair** Tadashi Matsushita (Department of Transfusion Medicine Nagoya University Hospital)
- Basics of the medical management for von Willebrand disease**
- Speaker** Kagehiro Amano (Department of Laboratory Medicine, Tokyo Medical University)
- Pathophysiology and Treatment of Acquired von Willebrand Syndrome**
- Speaker** Hideo Yagi (Nara Prefecture General Medical Center, Nara, Japan · Hematology and Oncology)
- Sponsor** Takeda Pharmaceutical Company Limited

MS2-9 Real-World Evidence of tazemetostat in relapsed/refractory follicular lymphoma

[No. 9 Tokyo International Forum 4F G402]

- Chair** Nobuhiko Uoshima (Department of Hematology, Japanese Red Cross Kyoto Daini Hospital)
- Speaker** Tsuyoshi Muta (Department of Blood Transfusion and Clinical Laboratory, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital)
- Sponsor** Eisai Co., Ltd.

MS2-10 Changes in AML treatment and outlook for the future

[No. 10 Tokyo International Forum 4F G409]

- Chair** Hiroki Yamaguchi (Department of Hematology, Nippon Medical School)
- Speaker** Akira Yokota (Department of Hematology, Chiba Aoba Municipal Hospital)
- Sponsor** Nippon Shinyaku Co., Ltd.

MS2-11

[No. 11 Tokyo International Forum 5F G502]

- Chair** Atae Utsunomiya (Department of Hematology, Imamura General Hospital)
- Treatment strategies for relapsed/refractory PTCL**
- Speaker** Yuko Shirouchi (Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
- Treatment of relapsed/refractory ATL: from the perspective of a dermatologist**
- Speaker** Kentaro Yonekura (Department of Dermatology, Imamura General Hospital)
- Sponsor** Meiji Seika Pharma Co., Ltd.

MS2-12 New treatment strategy for polycythemia vera

Live Recording On-demand

[No. 12 Tokyo International Forum 5F G510]

- Chair** Yuka Sugimoto (Department of Hematology and Oncology, Mie University Graduate School of Medicine)
- Clinical use of ropeginterferon alfa-2b**
- Speaker** Daigo Akahane (Department of Hematology, Tokyo Medical University)
- Basic research of ropeginterferon alfa-2b**
- Speaker** Kazuki Sakatoku (Department of Hematology, Osaka Metropolitan University Graduate School of Medicine)
- Sponsor** Medical Science, PharmaEssentia Japan KK

MS2-13 Disease Burden and Prevention of Respiratory Infectious Diseases (Pneumococcus, Influenza, COVID-19) in Hematopoietic Stem Cell Transplant Patients

[No. 13 Tokyo International Forum 6F G602]

Chair Yuki Asano-Mori (Toranomon Hospital, Tokyo, Japan)
Speaker Keiji Okinaka (National Cancer Center Hospital East, Chiba, Japan)
Sponsor MSD K.K. Medical Affairs

15-Oct (Sun) 8:00—8:45

MS3-3 Significance of BTK-i Treatment in CLL Treatment Strategy

[No. 3 Tokyo International Forum 7F Hall B7 ②]

Chair Shingo Yano (Department of Internal Medicine Division of Clinical Oncology/Hematology The Jikei University School of Medicine)

Relationship between ibrutinib and atrial fibrillation

Speaker Masaaki Shoji (National Cancer Center Hospital, Department of Cardiology)

Considerations on the Selection of BTK Inhibitors for the Treatment of CLL

Speaker Sadao Aoki (Niigata University of Pharmacy and Medical and Life Sciences)

Sponsor Janssen Pharmaceutical K.K.

Live Recording On-demand

MS3-4 Clinical Significance of MRD evaluation in Ph-positive leukemia

[No. 4 Tokyo International Forum 5F Hall B5 ①]

Chair Shinya Kimura (Saga University)

CML Management and Measurement of IS% With a Focus on Treatment Free Remission ~ From the Perspective of Practical Medicine.~

Speaker Masaki Iino (Yamanashi Prefectural Central Hospital)

MRD monitoring in Ph-positive ALL

Speaker Masahiro Onozawa (Hokkaido University)

Sponsor Otsuka Pharmaceutical Co., Ltd.

MS3-5 Indolent B-Cell Lymphomas in the 5th Edition of the WHO Classification of Hematolymphoid Tumors – What is New?

[No. 5 Tokyo International Forum 5F Hall B5 ②]

Chair Kennosuke Karube (Department of Pathology and Laboratory Medicine Graduate School of Medicine Nagoya University)

Speaker German Ott (Institut für Klinische Pathologie Robert-Bosch-Krankenhaus Stuttgart, Germany)

Sponsor Chugai Pharmaceutical Co., Ltd.

**MS3-6 Looking for New Ways of Care in Hematology
-Take Action for the Work Style Reforms of Doctors in 2024-**

Live Recording On-demand

[No. 6 Tokyo International Forum 7F Hall D7]

Chair Norimitsu Kadowaki (Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine Faculty of Medicine, Kagawa University, Kagawa, Japan)

Initiatives to Establish Regional Care System for the Treatment of Hematologic Disorders

Speaker Tatsuo Ichinohe (Department of Hematology, Hiroshima University Hospital, Hiroshima, Japan)

**Actionable Ways to Improve Workplace Environment in Hematology
-20 Years of sustainability progress in the Department of Hematology, Chiba University-**

Speaker Emiko Sakaida (Department of Hematology, Chiba University Hospital, Chiba, Japan)

Sponsor Novartis Pharma K.K.

MS3-7 Advances in the biology and treatment of Hodgkin lymphoma

[No. 7 Tokyo International Forum 5F Hall D5]

Chair Akihiro Tomita (Department of Hematology, Fujita Medical University School of Medicine)

Speaker Momoko Nishikori (Department of Human Health Sciences, Graduate School of Medicine, Kyoto University)

Sponsor ONO PHARMACEUTICAL CO., LTD./Bristol-Myers Squibb K.K.

**MS3-8 How will change Hemophilia A treatment ?
~Thinking about future treatment goals~**

[No. 8 Tokyo International Forum 1F Hall D1]

Chair Teruhisa Fujii (Hemophilia Treatment Center, Division of Transfusion Medicine, Hiroshima University Hospital)

Speaker Keiji Nogami (Department of Pediatrics, Nara Medical University)

Sponsor Sanofi K.K.

**MS3-9 New Strategies for the Treatment of Paroxysmal Nocturnal
Hemoglobinuria
~ Complement C3 Inhibitor ~**

[No. 9 Tokyo International Forum 4F G402]

Chair Kensuke Usuki (Department of Hematology, NTT Medical Center Tokyo)

Speaker Shinobu Tamura (Department of Emergency and Critical Care Medicine, Wakayama Medical University)

Sponsor Asahi Kasei Pharma Corporation

MS3-10 Biology and Treatment Strategies for T-cell lymphoma

[No. 10 Tokyo International Forum 4F G409]

Chair Shigeo Fuji (Department of Hematology, Osaka International Cancer Institute)

Immune microenvironments of angioimmunoblastic T-cell lymphoma

Speaker Mamiko Sakata-Yanagimoto (Department of Hematology, University of Tsukuba)

Treatment Strategies for Relapsed/Refractory PTCL

Speaker Tatsuro Jo (Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital)

Sponsor Medical HQs, Eisai Co., Ltd.

MS3-11 Treatment strategies for relapsed/refractory ALL

[No. 11 Tokyo International Forum 5F G502]

Chair Makoto Murata (Department of Hematology, Shiga University of Medical science, Japan)

Speaker Shinichi Kako (Division of Hematology, Jichi Medical University Saitama Medical Center, Japan)

Sponsor Pfizer Japan Inc.

MS3-12 Consider the future of management of patients with essential thrombocythemia

[No. 12 Tokyo International Forum 5F G510]

Chair Takayuki Tabayashi (Department of Hematology, Saitama Medical Center, Saitama Medical University)

Speaker Yoshinori Hashimoto (Department of Hematology, Tottori Prefectural Central hospital)

Sponsor Takeda Pharmaceutical Company Limited

14-Oct (Sat) 11 : 20 – 11 : 50

IS2-8 Up-to-date PNH clinical practice – Future direction of clinical practice based on the revision of PNH clinical reference guide –

Live Recording On-demand

[No. 8 Tokyo International Forum 1F Hall D1]

Chair Kaichi Nishiwaki (Division of Oncology and Hematology, The Jikei University Kashiwa Hospital)

Speaker Kohei Hosokawa (Kanazawa University Hospital)

Sponsor Medical Affairs Division, Alexion Pharma GK

15-Oct (Sun) 11 : 20 – 11 : 50

IS3-8 Patient Unmet Needs and Shared Decision in MDS

[No. 8 Tokyo International Forum 1F Hall D1]

Chair Ryosuke Ogawa (JCHO Kyushu hospital)

Speaker Esther Natalie Oliva (Department of Hematology, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Italy.)

Sponsor Bristol Myers Squibb Japan Medical

14-Oct (Sat) 12 : 00—12 : 45

JOOLS2-1 Hemophilia A Treatment Up Date

~ Hemostatic management with coagulation factor products ~

【Live Streaming Only】

- Chair** Azusa Nagao (Department of Blood Coagulation Ogikubo Hospital)
Speaker Nobuaki Suzuki (Nagoya University Hospital Department of Transfusion Medicine)
Sponsor Fujimoto Pharmaceutical Corporation

15-Oct (Sun) 12 : 05—12 : 50

JOOLS3-1 Optimization of acute lymphoblastic leukemia treatment : Including the use of Erwinase

【Live Streaming Only】

- Chair** Etsuko Yamazaki (Department of Hematology, Yokohama Rosai Hospital)
Speaker Katsuyoshi Koh (Department of Hematology/Oncology, Saitama Children's Medical Center)
Sponsor OHARA Pharmaceutical Co.,Ltd.